Race Oncology Share Price and Company Fundamentals
Last traded: Yesterday at 6:10 AM
Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein for treating for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.
|Primary activities||Precision oncology company|
|Industry / Sector||Biotechnology / Healthcare|
|Mailing address||Gateway, 1 Macquarie Place Level 36 Sydney NSW 2000 Australia|
|Phone / Fax||61 2 8051 3043 / 61 2 8051 3043|
|Share registry||AUTOMIC REGISTRY SERVICES|
Race Oncology does not pay dividends.
As of Sep 2021, following are the company executives and directors listed on Race Oncology.
|Mr. Phillip R. Lynch||CEO, MD & Director||4k|
|Dr. Daniel Tillett||Chief Scientific Officer & Exec. Director|
|Dr. David Everett Fuller BPharm, M.D., MBBS||Chief Medical Officer||56|
|Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D., MAICD||Company Sec.||57|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Race Oncology is 508.29M and its enterprise value is 498.97M. The enterprise value to revenue ratio of RAC is 1,288.04.
The RAC's stocks Beta value is 1.97 making it 97% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Race Oncology (RAC)
Race Oncology (ASX:RAC) Frequently Asked Questions
1. What is Race Oncology's Stock Symbol?
Race Oncology trades on ASX under the ticker symbol "RAC".
2. What is Race Oncology's stock price today?
One share of RAC stock can currently be purchased for approximately $3.52.
3. How can I contact Race Oncology?
Race Oncology's mailing address is Gateway, 1 Macquarie Place Level 36 Sydney NSW 2000 Australia. The company can be reached via phone at 61 2 8051 3043.
4. What is Race Oncology's official website?
The official website of Race Oncology is http://www.raceoncology.com.
5. Which share registry manages Race Oncology's stock?
Race Oncology's stock is managed by AUTOMIC REGISTRY SERVICES.